SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome

计划入组 40 人 · 首次发布于 2025 年 1 月 14 日

Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease

计划入组 75 人 · 首次发布于 2014 年 4 月 15 日

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

计划入组 24 人 · 首次发布于 2023 年 1 月 11 日

PAR2 inhibitors(Otsuka)

PAR2 Peptide(Sosei Heptares)

PAR2 mAb(Sosei Heptares)

PARK YONG HEE

France

PARI Pharma GmbH

Germany

Park Funding, LLC

United States

Domain Therapeutics to Showcase Novel GPCR-Targeting Oncology Programs at AACR 2025

SolasCure's Aurase Wound Gel Demonstrates 22x Faster Debridement in Phase II Chronic Wound Trial

Kainova Therapeutics Raises $32M CAD to Advance GPCR-Targeting Cancer and Inflammation Therapies